依托泊苷胶囊维持化疗对小细胞肺癌的疗效观察

Observation of the Efficacy of Etoposide Capsule Maitenance Therapy for Small Cell Lung Cancer

目的观察依托泊苷胶囊维持化疗对小细胞肺癌(SCLC)的疗效及生活质量的影响。方法 60例SCLC患者经EP方案化疗(依托泊苷联合顺铂)完全缓解后随机分为两组,实验组给予口服依托泊苷胶囊每天75 mg/m2,1~10天,休息2周,直至疾病进展;对照组停药观察,定期复查;出现复发或转移时再采用EP方案或其他二线或挽救方案化疗和(或)放疗。结果实验组与对照组中位无病生存期(DFS)分别为5个月和4个月(P<0.01)。1年生存率分别为86.67%和80.00%(P>0.05);2年生存率分别为33.33%和20.00%(P<0.05)。第12个月生存者KPS评分≥60分分别占96.15%和87.50%(P>0.05);第18个月生存者KPS评分≥60分分别占76.90%和66.70%(P<0.05)。结论口服依托泊苷胶囊维持化疗可延长小细胞肺癌患者的DFS及2年生存率,是一种安全有效的治疗方法。

Objective To observe the efficacy of etoposide capsule maintenance chemotherapy for small cell lung cancer(SCLC).Methods 60 patients with SCLC after EP regimen(etoposide and cisplatin) were randomly divided into 2 groups.The experiment group received etoposide 75 mg/m2/ d orally,1 ~ 10 d,with an interval of 2 weeks until disease progression; and the control group received medical observation and regular review,until recurrence or metastasis were given the EP regimen,second line,or save chemotherapy and(or) radiotherapy.Results The disease-free survival(DFS) in the experiment group and the control group were 5 months and 4 months,respectively(P < 0.01).The 1-year survival rates were 86.67% and 80.00%(P >0.05),respectively.The 2-year survival rates were 33.33% and 20.00%(P < 0.05),respectively.The rates of KPS ≥ 60 in 12 months were 96.15% and 87.50%(P > 0.05); the rates of KPS ≥ 60 in 18 months were 76.90% and 66.70%(P < 0.05).Conclusion The etoposide maintenance chemotherapy can prolong DFS and 2-year survival rate of patients with SCLC,it is a safe and effective treatment for SCLC.